---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-152016"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:44:18.305853+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade, intermediate risk NMIBC

## Summary
- SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.
- Primary endpoint: complete response rate at three months; initial CR data expected first half 2026.
- Patients randomized to 50 mg QD or 60 mg QD; additional dosing cohort may be evaluated.
- TYRA-300 also being studied in pediatric achondroplasia in BEACH301 Phase 2; first child dosing expected H2 2025.

## SEC filing metadata
- accession: 0001193125-25-152016
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/0001193125-25-152016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/d11524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-152016
- JSON: https://secwatch.observer/filing/0001193125-25-152016.json
- Plain text: https://secwatch.observer/filing/0001193125-25-152016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.